The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 371-377

  Brunner, Gerd ^a   Yang, Eric Y ^a   Kumar, Anirudh ^a   Sun, Wensheng ^a   Virani, Salim S ^a,b,c   Negi, Smita I ^d   Murray, Tyler ^a   Lin, Peter H ^a   Hoogeveen, Ron C ^a,b   Chen, Changyi ^a   Dong, Jing Fei ^e   Kougias, Panagiotis ^a,c   Taylor, Addison ^a,c   Lumsden, Alan B ^b   Nambi, Vijay ^a,b,c   Ballantyne, Christie M ^a,b   Morrisett, Joel D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ABI; Atherosclerosis; ICC; Lipids; Magnetic resonance imaging; MRI; PAD; PDW; Peripheral artery disease; SFA; T1W; T2W

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL FEMORAL ARTERY; TRIACYLGLYCEROL BLOOD LEVEL;

ABI; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; ICC; INTRA-CLASS CORRELATION; LIPIDS; MAGNETIC RESONANCE IMAGING; MRI; PAD; PDW; PERIPHERAL ARTERY DISEASE; PROTON-DENSITY-WEIGHTED; SFA; SUPERFICIAL FEMORAL ARTERY; T1-WEIGHTED; T1W; T2-WEIGHTED; T2W;

AGED; AZETIDINES; CHOLESTEROL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FEMORAL ARTERY; HUMANS; LIPIDS; LIPOPROTEINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NIACIN; PERIPHERAL ARTERIAL DISEASE; SIMVASTATIN;

EID: 84888105745     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.034     Document Type: Article

References (39)

1. Belch J.J., Topol E.J., Agnelli G., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med Apr 28 2003, 163(8):884-892.
2. Criqui M.H., Vargas V., Denenberg J.O., et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation Oct 25 2005, 112(17):2703-2707.
3. Hirsch A.T., Murphy T.P., Lovell M.B., et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 2007, 116(18):2086-2094.
4. Lumsden A.B., Rice T.W., Chen C., et al. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg Apr 2007, 31(4):695-704.
5. Joosten M.M., Pai J.K., Bertoia M.L., et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAm Med Assoc Oct 24 2012, 308(16):1660-1667.
6. Becker G.J., McClenny T.E., Kovacs M.E., Raabe R.D., Katzen B.T. The importance of increasing public and physician awareness of peripheral arterial disease. JVasc Interv Radiol Jan 2002, 13(1):7-11.
7. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med Dec 15 2011, 365(24):2255-2267.
8. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med Apr 29 2010, 362(17):1563-1574.
9. West A.M., Anderson J.D., Meyer C.H., et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis Apr 16 2011, 218(1):156-162.
10. Coppola G., Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res Jul 2007, 38(5):479-488.
11. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation Sep 23 2003, 108(12):1481-1486.
12. Schillinger M., Exner M., Mlekusch W., et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J May 2004, 25(9):742-748.
13. Berneis K., Rizzo M., Spinas G.A., et al. The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. Clin Chim Acta Aug 2009, 406(1-2):36-40.
14. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med Jul 22 2002, 162(14):1568-1576.
15. Blankenhorn D.H., Azen S.P., Crawford D.W., et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation Feb 1991, 83(2):438-447.
16. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation May 20 2003, 107(19):2409-2415.
17. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol Bull Mar 1979, 86(2):420-428.
18. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation Dec 3 2002, 106(23):2884-2887.
19. Adams G.J., Simoni D.M., Bordelon C.B., et al. Bilateral symmetry of human carotid artery atherosclerosis. Stroke Nov 2002, 33(11):2575-2580.
20. Murray D. Design and analysis of grouprandomized trials 1998, Oxford University Press Inc, New York, NY.
21. Snijders T.A.B., Bosker R.R.J. Multilevel analysis: an introduction to basic and advanced multilevel modeling. SAGE 1999.
22. Nunnally J.C., Bernstein I.H. Psychometric theory 1994, McGraw-Hill Inc;, New York.
23. Carod-Artal F.J., Ferreira Coral L., Stieven Trizotto D., Menezes Moreira C. Self- and proxy-report agreement on the stroke impact scale. Stroke Oct 2009, 40(10):3308-3314.
24. Etherington J., Innes G., Christenson J., et al. Development, implementation and reliability assessment of an emergency physician performance evaluation tool. CJEM Oct 2000, 2(4):237-245.
25. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEngl J Med Nov 29 2001, 345(22):1583-1592.
26. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JAm Coll Cardiol Dec 1986, 8(6):1245-1255.
27. Haynes R., Jiang L., Hopewell J.C., et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J May 2013, 34(17):1279-1291.
28. Rizzo M., Rini G.B., Spinas G.A., Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?. Atherosclerosis Jun 2009, 204(2):330-333.
29. Berneis K., Rizzo M., Berthold H.K., Spinas G.A., Krone W., Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J Jul 2010, 31(13):1633-1639.
30. Villines T.C., Stanek E.J., Devine P.J., et al. The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. JAm Coll Cardiol Jun 15 2010, 55(24):2721-2726.
31. Karmonik C., Basto P., Vickers K., et al. Quantitative segmentation of principal carotid atherosclerotic lesion components by feature space analysis based on multicontrast MRI at 1.5 T. IEEE Trans Biomed Eng Feb 2009, 56(2):352-360.
32. Brown R., Karmonik C., Brunner G., et al. Simultaneous bilateral magnetic resonance imaging of the femoral arteries in peripheral arterial disease patients. JMag Reson Imag 2011, 34(1):150-156.
33. Balu N., Wang J., Zhao X., Hatsukami T., Y C. Targeted multi-contrast vessel wall imaging of bilateral peripheral artery disease. Proceedings of the 18th annual meeting of ISMRM stockholm 2010.
34. Hellings W.E., Moll F.L., De Vries J.P., et al. Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. JAm Med Assoc Feb 6 2008, 299(5):547-554.
35. Rastan A., Tepe G., Krankenberg H., et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J Sep 2011, 32(18):2274-2281.
36. McDermott M.M., Liu K., Guralnik J.M., et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAm Med Assoc Jul 3 2013, 310(1):57-65.
37. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. NEngl J Med Nov 26 2009, 361(22):2113-2122.
38. Zhao X.Q., Dong L., Hatsukami T., et al. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging Sep 2011, 4(9):977-986.
39. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem Jun 1972, 18(6):499-502.